{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T06:17:33Z","timestamp":1792304253306,"version":"4.4.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.japh.2022.02.004","type":"journal-article","created":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T20:38:25Z","timestamp":1644525505000},"page":"674-682.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Systematic review of oral pharmacotherapeutic options for the management of uterine fibroids"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3476-8045","authenticated-orcid":false,"given":"Richard J.","family":"Rovelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole E.","family":"Cieri-Hutcherson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy C.","family":"Hutcherson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.japh.2022.02.004_bib1","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1089\/jwh.2018.7076","article-title":"Burden, prevalence, and treatment of uterine fibroids: a survey of U.S. Women","volume":"27","author":"Marsh","year":"2018","journal-title":"J\u00a0Womens Health (Larchmt)"},{"issue":"9252","key":"10.1016\/j.japh.2022.02.004_bib2","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(00)03622-9","article-title":"Uterine fibroids","volume":"357","author":"Stewart","year":"2001","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.japh.2022.02.004_bib3","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1097\/AOG.0000000000004401","article-title":"Management of symptomatic uterine leiomyomas: ACOG Practice Bulletin, number 228","volume":"137","year":"2021","journal-title":"Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.japh.2022.02.004_bib4","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.japh.2022.02.004_bib5","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/jebm.12141","article-title":"The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review","volume":"8","author":"Zeng","year":"2015","journal-title":"J\u00a0Evid Based Med"},{"issue":"3","key":"10.1016\/j.japh.2022.02.004_bib6","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.mjafi.2017.02.013","article-title":"A\u00a0randomized control trial to assess efficacy of mifepristone in medical management of uterine fibroid","volume":"73","author":"Arora","year":"2017","journal-title":"Med J Arm Force India"},{"issue":"1","key":"10.1016\/j.japh.2022.02.004_bib7","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1479-828X.2008.00931.x","article-title":"Low-dose mifepristone in treatment of uterine leiomyoma: a randomised double-blind placebo-controlled clinical trial","volume":"49","author":"Bagaria","year":"2009","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"10.1016\/j.japh.2022.02.004_bib8","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2147\/IJWH.S28103","article-title":"Mifepristone 2.5 mg versus 5 mg daily in the treatment of leiomyoma before surgery","volume":"4","author":"Carbonell Esteve","year":"2012","journal-title":"Int J Womens Health"},{"issue":"2","key":"10.1016\/j.japh.2022.02.004_bib9","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ejogrb.2011.12.018","article-title":"Treatment of uterine myoma with 5 or 10 mg mifepristone daily during 6 months, post-treatment evolution over 12 months: double-blind randomised clinical trial","volume":"161","author":"Carbonell Esteve","year":"2012","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.japh.2022.02.004_bib10","doi-asserted-by":"crossref","first-page":"649030","DOI":"10.1155\/2013\/649030","article-title":"Treatment of uterine myoma with 2.5 or 5 mg mifepristone daily during 3 months with 9 months posttreatment followup: randomized clinical trial","volume":"2013","author":"Carbonell","year":"2013","journal-title":"ISRN Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.japh.2022.02.004_bib11","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2147\/IJWH.S42770","article-title":"Mifepristone versus placebo to treat uterine myoma: a double-blind, randomized clinical trial","volume":"5","author":"Esteve","year":"2013","journal-title":"Int J Womens Health"},{"key":"10.1016\/j.japh.2022.02.004_bib12","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2147\/IJWH.S33125","article-title":"Safety and effectiveness of different dosage of mifepristone for the treatment of uterine fibroids: a double-blind randomized clinical trial","volume":"5","author":"Carbonell","year":"2013","journal-title":"Int J Womens Health"},{"issue":"2","key":"10.1016\/j.japh.2022.02.004_bib13","first-page":"243","article-title":"Low-dose mifepristone for uterine leiomyomata","volume":"101","author":"Eisinger","year":"2003","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.japh.2022.02.004_bib14","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jmig.2005.01.022","article-title":"Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas","volume":"12","author":"Eisinger","year":"2005","journal-title":"J\u00a0Minim Invasive Gynecol"},{"issue":"2","key":"10.1016\/j.japh.2022.02.004_bib15","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejogrb.2009.06.004","article-title":"Open-label study of ultra low-dose mifepristone for the treatment of uterine leiomyomata","volume":"146","author":"Eisinger","year":"2009","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"8","key":"10.1016\/j.japh.2022.02.004_bib16","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1093\/humrep\/dep100","article-title":"Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial","volume":"24","author":"Engman","year":"2009","journal-title":"Hum Reprod"},{"issue":"2","key":"10.1016\/j.japh.2022.02.004_bib17","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ijgo.2009.11.019","article-title":"Improved quality of life is partly explained by fewer symptoms after treatment of fibroids with mifepristone","volume":"109","author":"Feng","year":"2010","journal-title":"Int J Gynaecol Obstet"},{"issue":"6","key":"10.1016\/j.japh.2022.02.004_bib18","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1097\/01.AOG.0000243776.23391.7b","article-title":"Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial","volume":"108","author":"Fiscella","year":"2006","journal-title":"Obstet Gynecol"},{"issue":"7","key":"10.1016\/j.japh.2022.02.004_bib19","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.4103\/jfmpc.jfmpc_467_20","article-title":"A\u00a0prospective interventional study to evaluate the effects of medical therapy (mifepristone 25 mg) on the management of uterine fibroids","volume":"9","author":"Gupta","year":"2020","journal-title":"J\u00a0Family Med Prim Care"},{"issue":"2","key":"10.1016\/j.japh.2022.02.004_bib20","first-page":"65","article-title":"Mifepristone therapy in symptomatic leiomyomata using a variable dose pattern with a favourable outcome","volume":"9","author":"Jain","year":"2018","journal-title":"J\u00a0Midlife Health"},{"issue":"Suppl 1","key":"10.1016\/j.japh.2022.02.004_bib21","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s13224-016-0861-7","article-title":"Efficacy of use of long-term, low-dose mifepristone for the treatment of fibroids","volume":"66","author":"Kapur","year":"2016","journal-title":"J\u00a0Obstet Gynaecol India"},{"issue":"6","key":"10.1016\/j.japh.2022.02.004_bib22","first-page":"1154","article-title":"Low dose mifepristone in medical management of uterine leiomyoma - an experience from a tertiary care hospital from north India","volume":"137","author":"Kulshrestha","year":"2013","journal-title":"Indian J Med Res"},{"issue":"1","key":"10.1016\/j.japh.2022.02.004_bib23","first-page":"29","article-title":"Mifepristone in fibroids: an alternative!","volume":"10","author":"Roy","year":"2018","journal-title":"J\u00a0S Asian Fed Obstet Gynecol"},{"issue":"7","key":"10.1016\/j.japh.2022.02.004_bib24","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000006124","article-title":"Different dosages of mifepristone versus enantone to treat uterine fibroids: a multicenter randomized controlled trial","volume":"96","author":"Liu","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.japh.2022.02.004_bib25","doi-asserted-by":"crossref","first-page":"150","DOI":"10.4103\/0300-1652.86123","article-title":"A\u00a0study evaluating the effect of mifepristone (RU-486) for the treatment of leiomyomata uteri","volume":"52","author":"Mukherjee","year":"2011","journal-title":"Niger Med J"},{"issue":"2","key":"10.1016\/j.japh.2022.02.004_bib26","first-page":"513","article-title":"Regression of uterine leiomyomata in response to the antiprogesterone RU486","volume":"76","author":"Murphy","year":"1993","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.japh.2022.02.004_bib27","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0015-0282(16)57678-X","article-title":"Regression of uterine leiomyomata to the antiprogesterone RU486: dose-response effect","volume":"64","author":"Murphy","year":"1995","journal-title":"Fertil Steril"},{"issue":"2","key":"10.1016\/j.japh.2022.02.004_bib28","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1089\/gyn.2013.0082","article-title":"Role of low-dose mifepristone for managing uterine leiomyoma","volume":"30","author":"Nanda","year":"2014","journal-title":"J\u00a0Gynecol Surg"},{"issue":"6","key":"10.1016\/j.japh.2022.02.004_bib29","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0002-9378(94)70332-9","article-title":"The effects of RU486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: a prospective, randomized study","volume":"170","author":"Reinsch","year":"1994","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.japh.2022.02.004_bib30","first-page":"22","article-title":"Effect of mifepristone (25 mg) in treatment of uterine myoma in perimenopausal woman","volume":"4","author":"Seth","year":"2013","journal-title":"J\u00a0Midlife Health"},{"issue":"1","key":"10.1016\/j.japh.2022.02.004_bib31","first-page":"39","article-title":"Mifepristone in fibroids: comparative study of safety and efficacy of biweekly dosage vs daily dosage schedule","volume":"12","author":"Shaikh","year":"2021","journal-title":"J\u00a0Midlife Health"},{"issue":"2","key":"10.1016\/j.japh.2022.02.004_bib32","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.fertnstert.2018.10.012","article-title":"Vilaprisan in women with uterine fibroids: the randomized phase 2b ASTEROID 1 study","volume":"111","author":"Bradley","year":"2019","journal-title":"Fertil Steril"},{"issue":"1","key":"10.1016\/j.japh.2022.02.004_bib33","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejogrb.2020.05.043","article-title":"Efficacy and safety of vilaprisan in women with uterine fibroids: data from the phase 2b randomized controlled trial ASTEROID 2","volume":"252","author":"Gemzell-Danielsson","year":"2020","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"5","key":"10.1016\/j.japh.2022.02.004_bib34","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/cpdd.851","article-title":"Pharmacokinetics and safety of the selective progesterone receptor modulator Vilaprisan in Chinese health postmenopausal women","volume":"10","author":"Liu","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"8","key":"10.1016\/j.japh.2022.02.004_bib35","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1093\/humrep\/dew140","article-title":"Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in healthy women","volume":"31","author":"Sch\u00fctt","year":"2016","journal-title":"Hum Reprod"},{"issue":"2","key":"10.1016\/j.japh.2022.02.004_bib36","first-page":"229","article-title":"Effect of the novel selective progesterone receptor modulator vilaprisan on ovarian activity in healthy women","volume":"56","author":"Schutt","year":"2018","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.japh.2022.02.004_bib37","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJMoa2008283","article-title":"Treatment of uterine fibroid symptoms with Relugolix combination therapy","volume":"384","author":"Al-Hendy","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.japh.2022.02.004_bib38","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1186\/s12905-021-01475-2","article-title":"Relugolix for oral treatment of uterine leiomyomas: a dose-finding, randomized, controlled trial","volume":"21","author":"Hoshiai","year":"2021","journal-title":"BMC Womens Health"},{"issue":"3","key":"10.1016\/j.japh.2022.02.004_bib39","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/AOG.0000000000003141","article-title":"Oral gonadotropin-releasing hormone antagonist Relugolix compared with leuprorelin injections for uterine leiomyomas","volume":"133","author":"Osuga","year":"2019","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"10.1016\/j.japh.2022.02.004_bib40","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.fertnstert.2019.07.013","article-title":"Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: a randomized, placebo-controlled, phase 3 study in Japanese women","volume":"112","author":"Osuga","year":"2019","journal-title":"Fertil Steril"},{"issue":"1","key":"10.1016\/j.japh.2022.02.004_bib41","doi-asserted-by":"crossref","first-page":"72e1","DOI":"10.1016\/j.ajog.2020.07.032","article-title":"Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids","volume":"1","author":"Al-Hendy","year":"2020","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.japh.2022.02.004_bib42","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.fertnstert.2017.05.006","article-title":"Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study","volume":"108","author":"Archer","year":"2017","journal-title":"Fertil Steril"},{"issue":"5","key":"10.1016\/j.japh.2022.02.004_bib43","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1097\/AOG.0000000000002933","article-title":"Elagolix alone or with add-back therapy in women with heavy menstrual bleeding and uterine leuiomyomas: a randomized controlled trial","volume":"132","author":"Carr","year":"2018","journal-title":"Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.japh.2022.02.004_bib44","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1056\/NEJMoa1904351","article-title":"Elagolix for heavy menstrual bleeding in women with uterine fibroids","volume":"382","author":"Schlaff","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.japh.2022.02.004_bib45","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1097\/AOG.0000000000003869","article-title":"Elagolix treatment for up to 12 months in women with heavy menstrual bleeding and uterine leiomyomas","volume":"135","author":"Simon","year":"2020","journal-title":"Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.japh.2022.02.004_bib46","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1007\/s43032-020-00172-z","article-title":"Effects of combined GnRH receptor antagonist linzagolix and hormonal add-back therapy on vaginal bleeding-delayed add-back onset does not improve bleeding pattern","volume":"27","author":"Pohl","year":"2020","journal-title":"Reprod Sci"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319122000577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319122000577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:50:57Z","timestamp":1761544257000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319122000577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S1544319122000577"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2022.02.004","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic review of oral pharmacotherapeutic options for the management of uterine fibroids","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2022.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}